Schizophrenia Is Really Schizophrenias

We should not overlook the fact that schizophrenia is really schizophrenias (plural). For example pellagra, still around in many parts of the world, may be [mislabeled as schizophrenia]. Similarly, cerebral allergic reactions to gluten (gluteomorphin) can give rise to clinical features that would be [indistinguishable from schizophrenia], and therefore would be [overlooked by most psychiatrists].

Hoffer himself sometimes moved away from the adrenochrome hypothesis. For example, he advised us to think of alternate treatments (i.e., hypotheses) if a patient had not responded to therapeutic doses of niacin. Hoffer considered hypothyroidism as a possible cause of schizophrenia. He even quoted a study by Danziger that showed recoveries in 80 schizophrenic patients that were administered natural desiccated thyroid for at least 100 days, and who were ill for six months or less.

Foster, Pataracchia, Campbell McBride, and others have summarized the alternate causes or hypotheses of schizophrenia, such as subclinical hypothyroidism, cerebral allergy to gluten, sugar and petro chemical inhalants[HUFFING/VAPING?], heavy metal toxicity, and candida/gut  dysbiosis. In any individual case, any combination of causes might be implicated in the genesis of the schizophrenia syndrome.

Although, at least to my knowledge, adrenochrome has not been measured and compared between schizophrenic, nonschizophrenic and normal control groups of population, we can draw conclusions in favor of niacin and hence, indirectly for the adrenochrome hypothesis, from Hoffer’s studies and reports that spanned many decades. Outside of Hoffer, there have been publications giving indirect credence to the adrenochrome hypothesis. For example, Wittenborn published data demonstrating that acute-onset patients (ill for six months or less) were having intact inter-personal relations as a result of niacin treatment.

Hoffer’s writings also stressed the value of psychosocial factors when he talked of food, shelter, and respect as critically valuable factors in recovery without psychiatric drugs. In the case of chronic schizophrenic patients, who are likely to develop negative symptoms, much like the well known symptoms of “institutionalization or hospitalization syndrome,” the useful hypothesis may be something other than the adrenochrome hypothesis. There is even evidence of gluten sensitivity in chronic schizophrenic patients. They may have become chronic because the treating physician didn’t consider gluten as a hypothesis of schizophrenia. A 2009 publication described a lifelong schizophrenic patient that recovered following a gluten-free, low-carbohydrate ketogenic diet.

PDF – The Adrenochrome Hypothesis

Schizophrenia, Cancer and the Hoff

Schizophrenia and cancer: the adrenochrome balanced morphism.


Cancer might be expected to be more common amongst schizophrenics than the general population. They frequently live in selenium deficient regions, have seriously compromised antioxidant defense systems and chain-smoke. The available literature on the cancer-schizoprenia relationship in patients from England, Wales, Ireland, Denmark, USA and Japan, however, strongly suggests that the reverse is true. One of the authors (Hoffer) has treated 4000 schizophrenics since 1952. Only four of these patients has developed cancer.

Since low cancer incidence has been recorded amongst patients treated by both conventional physicians using pharmaceuticals and by orthomolecular doctors who emphasize vitamins and minerals, it follows that this depressed cancer incidence must be related to the biochemistry of the disorder itself. Taken as a whole, therefore, the evidence seems to suggest that schizophrenics, their siblings and parents are less susceptible to cancer than the general population.

These relationships seem compatible with one or more genetic risk factors for schizophrenia that offer(s) a selective advantage against cancer. There is experimental evidence that appears to support this possibility. Matrix Pharmaceuticals Inc. has received a US patent covering the composition of IntraDose Injectable Gel. This gel contains cisplatin and epinephrine (adrenaline) and is designed to be injected directly into tumor masses. Cisplatin is a very powerful oxidant which will almost certainly rapidly convert the adrenaline to adrenochrome. While the manufacturers of IntraDose consider cisplatin to be the active cytotoxic agent in IntraDose, it seems more likely that adrenochrome and its derivatives may, in fact, be more effective.

IntraDose gel has undergone or is undergoing a series of Phase III open-label clinical studies, being injected into patients’ tumors that have been identified as the most troublesome by their physicians. The results have been impressive for breast cancer, malignant melanoma, esophageal cancer and cancer of the head, neck and liver. The evidence suggests that there are balanced morphisms in schizophrenia that result in above normal exposure to catecholamine derivatives. Since such catecholamines are both hallucinogenic and anti-carcinogenic abnormally high exposure to them simultaneously increases susceptibility to schizophrenia and reduces the probability of developing cancer.

These observations have significant implications for the treatment of both illnesses.